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Occurrences of HIV-1 superinfection offer a unique opportunity to investigate the correlates of immune protection. Here we describe the
neutralizing antibody responses of a cohort of recently infected individuals who were screened for HIV superinfection. Three individuals
identified with HIV superinfection had less cross-protective and autologous neutralizing antibody response than their non-superinfected case–
controls. Neutralizing antibody may be crucial in the protection against superinfection and may explain why superinfection has only been
documented following recent infection or treatment interruption. These data have considerable implications for vaccine development.
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Most reports of intraclade HIV-1 superinfection have been
described during primary infection (Jost et al., 2002; Koelsch et
al., 2003; Yang et al., 2005; Smith et al., 2005a,b) or during a
structured treatment interruption when the patient initiated
antiretroviral therapy during primary infection (Altfeld et al.,
2002). Both situations are associated with a relatively weaker
cell-mediated and humoral immunologic response to autologous
and heterologous viruses than is chronic untreated infection
(Binley et al., 2004; Richman et al., 2003; Altfeld et al., 2002;
Ortiz et al., 2001). Superinfection in humans, however, has been
reported to occur even when there are broad CD8+ T-cell⁎ Corresponding author. University of California San Diego, Stein Building
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doi:10.1016/j.virol.2006.08.009responses to the primary virus, but the superinfecting virus in
these cases did not share apparently important epitopes with the
initial strain (Altfeld et al., 2002; Yang et al., 2005; Jost et al.,
2002). Animal models suggest a role for neutralizing antibody
(NAb) in the protection against superinfection (Shibata et al.,
1996) and even against primary infection (Nishimura et al.,
2002; Parren et al., 2001). To investigate this we performed a
case–control study within a cohort previously screened for
superinfection to examine NAb as a correlate of immune
protection from superinfection during primary infection.
Results and discussion
All superinfected patients lacked detectable NAb to hetero-
logous laboratory strains at baseline, which was significantly
different than the detection of NAb in the non-superinfected
control group (Fisher's exact: NL4-3 p=.02; JRCSF p=.05). A
weak response to autologous virus could be detected in only one
2 Rapid Communicationof the three superinfected patients, suggesting a weaker
response to autologous HIV-1 in these patients than in the 11
control patients (Fisher's exact; p= .09) (Fig. 1A). Two control
patients (114 and 127) also had very little detectable NAb to
NL4-3, which might mean that they were susceptible to
superinfection but other factors may have prevented super-
infection like degree of risk exposure.
The clinical significance of in vitro neutralization of
laboratory strains remains unclear since NL4-3 is quite sensitive
to antibody neutralization in the assay used (Richman et al.,
2003). A trend (Mann–Whitney; p=.09) toward a longer delay
between the estimated date of infection and study enrollment
was observed among the superinfected group (mean 98 days)
compared to the control group (mean 72 days) (Table 1). SinceFig. 1. Neutralizing antibody responses. (A) Neutralizing antibody responses at base
(dashed black line) in only 1/9 samples from superinfected patients vs. 28/33 samples
screening for superinfection, all superinfected patients lacked detectable neutraliz
Responses to autologous virus (Auto) could be detected in only one of the three patien
than in the 11 control patients. (B) Neutralizing antibody responses at 6 months, repre
S2 was unable to be reconstructed in the recombinant assay (*). Therefore, the neutr
comparing NAb response to simultaneous autologous virus at 6 months, there was sig
was also a trend for less NAb response to JRCSF (p=0.08) and baseline (p=0.12)the NAb responses increase throughout natural infection, this
trend would theoretically bias the NAb titers to be higher in the
superinfected group than the controls, in contrast to what was
observed, which further underscores the observation that the
superinfected group had less neutralizing antibody than the
control group. We then investigated if the strength of NAb
response correlated within individuals across all viruses tested
at both baseline and six-month timepoints (i.e. did individuals
with weaker NAb responses to one virus have weaker responses
to other viruses?). We found a significant direct correlation
between NAb responses to all three viruses at baseline.
Measurements at 6 months, however, revealed that only the
responses to the six-month autologous and JRCSF viruses
remained significantly correlated (Supplementary Table 1).line. Baseline neutralizing antibody could be detected at the threshold 20:1 titer
from patients without evidence of superinfection (p<0.001). At time of baseline
ing antibody to heterologous clones NL4-3 (p=0.02) and JR-CSF (p=0.05).
ts (p=0.09), suggesting a weaker response to autologous HIV-1 in these patients
senting after superinfection in the superinfected group. The six-month virus from
alization sensitivity for this virus at this timepoint is unknown. However, when
nificantly less response in the superinfected group (S1 and S3) (p=0.02). There
viruses at 6 months, while there was no difference in responses to NL4-3.
Table 1
Patient summary
Patient Age HIV RNA
(Log c/ml)
ΔHIV RNA CD4 ΔCD4 Estimated days of
infection at time of
NAb measurement
S1 36 3.08 1.76⁎ 571 −197 85
S2 33 3.38 2.80⁎ 711 −385 84
S3 33 2.91 1.96⁎ 616 −85 126
62 44 5.70 −2.01 552 −83 82
83 64 2.75 .28 1119 −383 67
114 63 3.24 − .70 492 −30 83
127 38 6.26 − .59 492 −199 43
151 35 3.89 − .10 557 −172 107
169 48 5.42 − .09 692 −165 182
181 36 5.27 .00 689 −207 45
216 37 3.07 .80 391 −95 73
218 47 5.46 − .20 311 −9 24
226 34 4.88 − .53 362 −68 55
231 31 4.28 − .58 557 −132 32
There were no significant differences in age or baseline CD4 count between the
superinfected patients (bold) (S1, S2 and S3) and the controls. There were no
significant differences between the two groups in the changes in CD4 counts
(ΔCD4) over the 6 months after the first antibody measurement, which
represented before and after superinfection in the superinfected group. However,
there was a trend for baseline viral loads (Mann–Whitney; p=0.12) to be lower
in the superinfected group. Viral loads increased significantly (ΔHIV RNA) in
the superinfected group over the study period, indicating significantly poorer
control of plasma viremia than in control patients (p=0.02⁎). There was a trend
(Mann–Whitney; p=0.09) toward a longer delay between the estimated date of
infection and study enrollment among superinfected patients (mean 98 days)
than non-superinfected patients (mean 72 days). This suggests a bias toward
more mature antibody responses in the superinfected group, further under-
scoring the relative weakness of antibody responses in the superinfected
patients.
3Rapid CommunicationAdditionally, a recent report has demonstrated a positive
correlation between heterologous NAb response and viral load
(Deeks et al., 2006), which is in contrast to our superinfected
group that demonstrated low viral loads despite low hetero-
logous NAb responses (Supplementary Fig. 1). Perhaps, this
discrepancy may be explained by vigorous cell-mediated
responses, which are associated with lower HIV viral loads
(Ogg et al., 1998), among these individuals prior to their
superinfection, which has also been described previously (Yang
et al., 2005; Altfeld et al., 2002). Taken together, these data may
lend further evidence that a preventative HIV vaccine based
solely on boosting the cell-mediated response may be
inadequate.
In the superinfected patients, NAb responses to the baseline
autologous and laboratory strain viruses were stronger after
superinfection (Fig. 1B), especially the responses to NL4-3,
which were no longer different between the two groups
6 months later. However, there still remained a trend for
lower NAb levels in the superinfected group to baseline
autologous virus (Mann–Whitney; p=.12) and JRCSF (Mann–
Whitney; p=.08) (Fig. 1B). There was also a weak trend
(Mann–Whitney; p=.12) for the superinfected group to have
lower baseline viral loads, which could represent either initial
infection with a less virulent virus or that the superinfected
group, who was farther along in their infection, was closer to
their viral setpoint than the control group whose viral loads wereelevated secondary to a more recent infection (Table 1). This is
further highlighted by the significant increases in viral loads
over the study period that occurred in the superinfected group
(Mann–Whitney; p=.02) (Supplementary Fig. 1). It remains
unclear how superinfection may effect HIV disease progression
since the reductions in CD4 count were not statistically
significant between the two groups (Mann–Whitney; p=.29)
(Table 1). No significant differences in env glycosylation (data
not shown), which have been shown to influence Nab activity
(Wei et al., 2003), or genetic distances between viruses were
observed between the two groups and either laboratory strain
NL4-3 (R2 = .012) or JRCSF (R2 = .10) (Supplementary Fig. 2).
Similarly, an inferred maximum likelihood phylogenetic
reconstruction of the V3 coding region of the env sequences
showed no differences between baseline viruses of the super-
infected and non-superinfected individuals as compared to
JRCSF and NL4-3 (Supplementary Fig. 3). From the super-
infected individuals, the baseline (initial strain) and six-month
(superinfecting strain) viruses were significantly different from
each other confirming the incidences of superinfection, as
previously described (Smith et al., 2005a,b). Furthermore, all
baseline and superinfecting viruses used the CCR5 coreceptor
as would be expected in primary infection (data not shown)
(Connor et al., 1997).
Intraclade superinfection has been difficult to identify, and
this report includes three of the reported seven cases (Smith et
al., 2005a,b). Despite the small number of superinfected cases
investigated, this study demonstrates that individual immune
responses to primary HIV infection vary in breadth and
magnitude, but that the absence of heterologous neutralizing
activity probably predisposes to superinfection. The level and
cross-reactivity of NAb required to protect an individual from
superinfection will require characterization of additional cases.
Current efforts to develop candidate HIV vaccines must
consider these ‘natural’ immunization failures in the hopes of
better understanding the role of virus-specific host immune
responses (Smith et al., 2005a,b). These provocative data
suggest the role of cross-protective neutralizing antibody in the
prevention of superinfection and elucidate important goals for
protective vaccine design.
Methods
We performed a case–control study, matched for primary
HIV infection (<6 months) and acknowledged continuing
male homosexual HIV risk exposures (4 to >100 reported
exposures during the first 6 months of their infection),
within a cohort previously screened for superinfection (Smith
et al., 2004). Neutralizing antibody, CD4 and viral load
measurements and HIV env sequences (gp120) (Monogram
Biosciences Inc., South San Francisco) were obtained for the
first eleven matched individuals within the San Diego
AIEDRP cohort who screened negative for intraclade
superinfection (controls) and the three individuals who
became intraclade superinfected (cases). Based on previous
investigations and internal validation of the assay, a thresh-
old of 20:1 was used to identify significant NAb responses
4 Rapid Communication(Richman et al., 2003). Responses were measured against
autologous and clade B laboratory virus strains (NL4-3 and
JRCSF) with the first available blood sample (baseline) and
6 months later (Table 1). For the superinfected individuals,
these timepoint samples represent before and after super-
infection. Estimated date of first HIV infection was based
upon the standardized AIEDRP algorithm (http://www.aiedrp.
org/). Briefly, the rules for estimated date of infection are
listed in order of application: (1) if HIV enzyme immu-
noassay (EIA) is negative and HIV viral load is >5000
copies/ml, use the date 21 days prior; (2) if HIV EIA is
positive and Western Blot is indeterminate, use the date 28
days prior to indeterminate Western Blot; (3) If HIV EIA is
positive and Western Blot is positive, but ≤5 bands, then
use the date 45 days prior; (4) if HIV EIA is positive and
Western Blot is positive (i.e. ≥5 bands positive) and a
detuned EIA (Vironostika) value is ≤1.0 and the CD4 cell
percentage is greater than 14%, then use the date 85 days
prior; (5) if none of the previous criteria is met, then use the
midpoint between the date of the first documented positive
EIA and the last historically documented negative EIA,
which must be less than 365 days prior to enrollment.
The significance of comparisons between groups was
assessed by non-parametric methods; a Fisher's exact test was
used for categorical comparisons, Wilcoxon paired test for
comparisons between antibody responses and the two-tailed
Mann–Whitney test in all others. Logarithmic viral load and
CD4 count changes were computed as a least-squares linear fit
to all available data from the first year on study. Glycosylation
pattern (Marshall, 1974), coreceptor usage (Pillai et al., 2003)
and genetic distances were computed from the gp120 env
nucleotide sequences, and phylogenetic reconstruction was
performed using Phylogeny Inference Package software of the
C2-V3 coding region of env nucleotide sequences (Felsenstein,
1993).
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